FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(37 CFR 1.98(b)

(Use several sheets if necessary)

ATTY.	DOCKE	T NO.
TTOD		COLD

USB95AR CNR KDR

SERIAL NO

APPLICANT

Jean PLOUET et al.

FILING DATE

June 22, 1998

GROUP

1644

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	_	PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						÷
	AE						
	AF						
	AG						

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

		DOCUMENT NO.	PUBL. DATE	COUNTRY OR PATENT OFFICE	CLASS	SUB CLASS	TRANSLATION YES NO
-	AL	0 502 416	9/92	Europe			yes
138	АМ	WO 94/11499	5/94	International			yes
	AN						
	AO						
ī	AP						

OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of **Publication**)

,	SPZ	AR -	by Plouet et al., "VEGF Dependent Tumoral Progression: Stimulation by Anti VEGF Idiotypic Antibodies", <u>JOURNAL OF</u> <u>CELLULAR BIOCHEMISTRY</u> , Supplement 18A, 1994, page 328.
L;	89_	AS	by Terman et al., "Identification of the KDR Tyrosine Kinase as a Receptor for Vascular Endothelial Cell Growth Factor", <u>BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICA-TIONS</u> , Vol. 187, No. 3, 1992, pages 1579-1586.
۶	SPE	AT	by Millauer et al., "High Affinity VEGF Binding and Developmental Expression Suggest Flk-1 as a Major Regulator of Vasculogenesis and Angiogenesis", <u>CELL</u> , Vol. 72, 1993, pages 835-846

EXAMINER

DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use several sheets if necessary)

(37 CFR 1.98(b)

ATTY. DOCKET NO.
USB95AR CNR KDR

APPLICANT

Jean PLOUET et al.

FILING DATE

June 22, 1998

GROUP 1644

U.S. PATENT DOCUMENTS ISSUE **EXAMINER** SUB **FILING DATE** INITIAL PATENT NUMBER DATE **PATENTEE** CLASS CLASS IF APPROPRIATE AA AB AC AD AE AF AG AHFOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION PUBL. SUB **TRANSLATION** DOCUMENT NO. DATE **COUNTRY OR PATENT OFFICE** CLASS CLASS AL AM AN AO AP OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication) AR by Millauer et al., "Glioblastoma Growth Inhibited in vivo by a Dominant-Negative Flk-1 Mutant", NATURE, Vol. 367, 1994, pages 576-579. by Kim et al., "Inhibition of Vascular Endothelial Growth Factor-Induced Angiogenesis Suppresses Tumour Growth in vivo", NATURE, Vol. 362, 1993, pages 841-844. by Chagnaud et al., "Curative Effects on Rat Sarcomas Obtained After a Treatment Combining Two Monoclonal Antibodies", ANTI-CANCER DRUGS, Vol. 5, 1994, pages 361-366. **EXAMINER** DATE CONSIDERED Fueldt

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO. USB95AR CNR KDR SERIAL NO.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use several sheets If necessary)

(37 CFR 1.98(b)

APPLICANT Jean PLOUET et al.

FILING DATE

June 22, 1998

GROUP 1644

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	AA						
	АВ						
	AC						
	AD						
	AE						
	AF						
	AG						
	АН						·
	Al						
	FOF	REIGN PATENT OI	R PUBLIS	HED FOREIGN PATENT	APPL	CATION	
	,	DOCUMENT NO.	PUBL. DATE	COUNTRY OR PATENT OFFICE	CLASS	SUB CLASS	TRANSLATION YES NO
	AL						
	АМ						
	AN						

OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of **Publication**)

889 ·	AR	by Ortega et al., "Modulation de la Progression Tumoral No par des Anticorps Anti-Idiotypiques de Facteurs Truspitales Angiogeniques", C.R. ACAD. SCI. PARIS, SCIENCE DE LA VIE, Vol. 319, 1996, pages 411-415. Abstract Daly
	AS	
	AT	•

EXAMINER

AO AP

Fwold

DATE CONSIDERED

4/26/00

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.